miochol-e 10 mg/ml jauhe ja liuotin instillaatioliuosta varten, silmän sisään
dr. gerhard mann chem.-pharm. fabrik gmbh - acetylcholine chloride - jauhe ja liuotin instillaatioliuosta varten, silmän sisään - 10 mg/ml - asetyylikoliini
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
vyvgart
argenx - efgartigimod alfa - myasthenia gravis - immunosuppressantit - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.
bisolaclar 600 mg poretabletti
opella healthcare france sas - acetylcysteine - poretabletti - 600 mg - asetyylikysteiini
mucomyst 200 mg poretabletti
viatris oy - acetylcysteine - poretabletti - 200 mg - asetyylikysteiini
equimucin vet 2 g jauhe
cp-pharma handelsgesellschaft mbh - acetylcysteine - jauhe - 2 g - asetyylikysteiini
meditus 200 mg poretabletti
orion corporation - acetylcysteine - poretabletti - 200 mg - asetyylikysteiini
mucoratio 200 mg poretabletti
teva b.v. - acetylcysteine - poretabletti - 200 mg - asetyylikysteiini
mucoratio 600 mg poretabletti
teva b.v. - acetylcysteine - poretabletti - 600 mg - asetyylikysteiini
stromease 25 mg/ml silmätipat, liuos
domes pharma - acetylcysteine - silmätipat, liuos - 25 mg/ml - asetyylikysteiini